Moreno-Bost, Amberly <br/><br/>
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.  [electronic resource] 

 -  Cytotherapy  May 2011 
 - 618-28 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1477-2566 
<br/><br/><label>Standard No.: </label>10.3109/14653249.2010.529893  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, Neoplasm--genetics<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Azacitidine--therapeutic use<br/>Benzamides--therapeutic use<br/>Cell Line, Tumor<br/>DNA Methylation--drug effects<br/>Epigenesis, Genetic--drug effects<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Histone Deacetylase Inhibitors--therapeutic use<br/>Humans<br/>Male<br/>Multiple Myeloma--genetics<br/>Neoplasm Proteins--genetics<br/>Pyrimidines--therapeutic use<br/>Secondary Prevention<br/>T-Lymphocytes, Cytotoxic--immunology